Somatostatin in the central nervous system: physiology and pathological modifications

Area of Science:

• Neuroscience
• Endocrinology
• Biochemistry

Background:

• Somatostatin, discovered in 1973, exhibits diverse actions and wide distribution.
• Its biochemical pathways and neuronal release mechanisms are understood, but a definitive neurotransmitter role for somatostatin peptides beyond somatostatin-14 remains unproven.
• The peptide's poor pharmacology hinders precise determination of its brain functions.

Purpose of the Study:

• To explore the neurotransmitter role of somatostatin peptides in the brain.
• To highlight the need for improved pharmacological tools, such as receptor antagonists.
• To investigate the potential involvement of somatostatin in neurological diseases like Alzheimer's and Huntington's.

Main Methods:

• Review of existing literature on somatostatin's actions, distribution, and pathways.
• Analysis of current understanding of somatostatin's mechanisms of action, particularly in pituitary models.
• Discussion of challenges in studying somatostatin's brain function and its role in disease.

Main Results:

• While somatostatin's general actions are documented, its specific neurotransmitter role in the brain is not definitively established.
• The pituitary model offers insights into somatostatin's mechanisms, potentially applicable to brain cells.
• Somatostatin's role in the pathophysiology of neurological disorders is a significant area for future research.

Conclusions:

• Further research, particularly with novel pharmacological tools, is essential to elucidate somatostatin's neurotransmitter functions in the brain.
• Understanding somatostatin's mechanisms in the pituitary may provide a framework for studying its effects on brain cells.
• The potential link between somatostatin and neurodegenerative diseases warrants continued investigation.